Onconova Therapeutics, Inc. (ONTX): Price and Financial Metrics


Onconova Therapeutics, Inc. (ONTX): $1.15

0.03 (+2.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ONTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ONTX POWR Grades


  • Sentiment is the dimension where ONTX ranks best; there it ranks ahead of 98.75% of US stocks.
  • ONTX's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
  • ONTX's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

ONTX Stock Summary

  • For ONTX, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • ONTX's price/sales ratio is 179.37; that's higher than the P/S ratio of 98.53% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ONTX comes in at -137.06% -- higher than that of only 2.58% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Onconova Therapeutics Inc are NAVB, AEIS, MYSZ, GEOS, and SCYX.
  • ONTX's SEC filings can be seen here. And to visit Onconova Therapeutics Inc's official web site, go to www.onconova.com.

ONTX Valuation Summary

  • ONTX's price/earnings ratio is -3.9; this is 110.68% lower than that of the median Healthcare stock.
  • Over the past 99 months, ONTX's price/sales ratio has gone up 347.8.
  • Over the past 99 months, ONTX's price/sales ratio has gone up 347.8.

Below are key valuation metrics over time for ONTX.

Stock Date P/S P/B P/E EV/EBIT
ONTX 2021-08-31 356.4 2.5 -3.9 -1.9
ONTX 2021-08-30 347.9 2.5 -3.8 -1.8
ONTX 2021-08-27 349.2 2.5 -3.8 -1.8
ONTX 2021-08-26 351.3 2.5 -3.8 -1.8
ONTX 2021-08-25 342.4 2.4 -3.7 -1.7
ONTX 2021-08-24 335.6 2.4 -3.7 -1.6

ONTX Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 327.26%.
  • Its 3 year net income to common stockholders growth rate is now at -22.29%.
  • Its year over year price growth rate is now at 70.98%.
Over the past 67 months, ONTX's revenue has gone down $12,589,000.

The table below shows ONTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0.227 -20.69 -18.828
2021-06-30 0.236 -22.186 -21.616
2021-03-31 0.235 -23.26 -24.78
2020-12-31 0.231 -23.075 -25.157
2020-09-30 0.204 -22.967 -24.475
2020-06-30 0.201 -21.165 -22.829

ONTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ONTX has a Quality Grade of D, ranking ahead of 8.68% of graded US stocks.
  • ONTX's asset turnover comes in at 0.007 -- ranking 403rd of 682 Pharmaceutical Products stocks.
  • IDRA, MYMD, and CAPR are the stocks whose asset turnover ratios are most correlated with ONTX.

The table below shows ONTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.007 1 2.820
2021-03-31 0.008 1 3.136
2020-12-31 0.009 1 3.246
2020-09-30 0.007 1 3.342
2020-06-30 0.009 1 3.259
2020-03-31 0.123 1 2.890

ONTX Price Target

For more insight on analysts targets of ONTX, see our ONTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $0.30 Average Broker Recommendation 1.5 (Moderate Buy)

ONTX Stock Price Chart Interactive Chart >

Price chart for ONTX

ONTX Price/Volume Stats

Current price $1.15 52-week high $8.00
Prev. close $1.12 52-week low $1.00
Day low $1.11 Volume 51,600
Day high $1.17 Avg. volume 154,600
50-day MA $1.48 Dividend yield N/A
200-day MA $2.71 Market Cap 24.03M

Onconova Therapeutics, Inc. (ONTX) Company Bio


Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer.


ONTX Latest News Stream


Event/Time News Detail
Loading, please wait...

ONTX Latest Social Stream


Loading social stream, please wait...

View Full ONTX Social Stream

Latest ONTX News From Around the Web

Below are the latest news stories about Onconova Therapeutics Inc that investors may wish to consider to help them evaluate ONTX as an investment opportunity.

Onconova Therapeutics (ONTX) Investor Presentation IP - Slideshow

No summary available.

Seeking Alpha | February 11, 2022

Onconova Therapeutics to Present at the Guggenheim Oncology Conference

NEWTOWN, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Guggenheim Oncology Conference taking place virtually February 9, 2022, through February 11, 2022. Steven Fruchtman, M.D., President & CEO of Onconova, will participate in a fireside chat on February 10, 2022, at 8:30 a.m. E

Yahoo | February 2, 2022

Onconova Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

NEWTOWN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10, 2022, through January 13, 2022. A corporate overview presented by Steven Fruchtman, M.D., President & CEO of Onconova, will be available on-demand beginn

Yahoo | January 4, 2022

Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development

NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development. “Adar’s deep scientific expertise in oncology and business development experience at leading biotechnology companies, most recently at Amgen, make her an excellent addition to our

Yahoo | December 13, 2021

We're Not Very Worried About Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 6, 2021

Read More 'ONTX' Stories Here

ONTX Price Returns

1-mo -17.27%
3-mo -29.01%
6-mo -61.67%
1-year -82.81%
3-year -97.63%
5-year -99.73%
YTD -54.90%
2021 -63.50%
2020 21.62%
2019 -81.85%
2018 -90.62%
2017 -33.92%

Continue Researching ONTX

Want to see what other sources are saying about Onconova Therapeutics Inc's financials and stock price? Try the links below:

Onconova Therapeutics Inc (ONTX) Stock Price | Nasdaq
Onconova Therapeutics Inc (ONTX) Stock Quote, History and News - Yahoo Finance
Onconova Therapeutics Inc (ONTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6323 seconds.